| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Keros Therapeutics, Inc. (KROS) has 8 insiders with recent SEC Form 4 filings, including 2 buys and 0 sells. KROS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 759.2K | $8.03M | - | |
| Dir | 759.2K | $8.03M | - | |
| Dir | 102.2K | $1.08M | - | |
| CEO | 62.5K | $661.4K | - | |
| Dir | 17.6K | $186.2K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Apr 13, 2020 | Gordon Carl L74 | Director | Buy | 375,200 | $16.00 | $6,003,200.00 | +50.4% | |
| Apr 13, 2020 | Arkin Bio Ventures Limited Partnership | 10% Owner | Buy | 120,000 | $16.00 | $1,920,000.00 | +6.3% |